西亚试剂::miR-214 targets ATF4 to inhibit bone formation
发布时间:2025-11-12
Xiaogang Wang, Baosheng Guo, Qi Li, Jiang Peng, Zhijun Yang, Aiyuan Wang, Dong Li, Zhibo Hou, Ke Lv, Guanghan Kan, Hongqing Cao, Heng Wu, Jinping Song, Xiaohua Pan, Qiao Sun, Shukuan Ling, Yuheng Li, Mu Zhu, Pengfei Zhang, Songlin Peng, Xiaoqing Xie, Tao Tang, An Hong, Zhaoxiang Bian, Yanqiang Bai, Aiping Lu, Yinghui Li, Fuchu He, Ge Zhang & Yingxian Li
Emerging evidence indicates that microRNAs (s) have important roles in regulating osteogenic differentiation and bone formation. Thus far, no study has established the pathophysiological role for miRNAs identified in human osteoporotic bone specimens. Here we found that elevated miR-214 levels correlated with a lower degree of bone formation in bone specimens from aged patients with fractures. We also found that osteoblast-specific manipulation of miR-214 levels by miR-214 antagomir treatment in miR-214 transgenic, ovariectomized, or hindlimb-unloaded mice revealed an inhibitory role of miR-214 in regulating bone formation. Further, in vitro osteoblast activity and matrix mineralization were promoted by antagomir-214 and decreased by agomir-214, and miR-214 directly targeted ATF4 to inhibit osteoblast activity. These data suggest that miR-214 has a crucial role in suppressing bone formation and that miR-214 inhibition in osteoblasts may be a potential anabolic strategy for ameliorating osteoporosis.
上一篇:西亚试剂:3D细胞培养,让细胞有家的感觉下一篇:西亚试剂:人类蛋白质组草图里程碑成果公布



鲁ICP备20015914号-4